AOD-9604 Research Guide: Sequence, Specs & COA Checks

AOD-9604 Research Guide: Sequence, Specs and COA Checks

Researchers evaluating AOD-9604 should separate published experimental findings from supplier claims. This guide focuses on compound identity, study context, analytical specifications, and documentation checks. It is not a dosing or treatment guide.

Before procurement, review the current AOD-9604 research product page, compare available records in the lab-report index, and use the COA reading guide to match each report to its lot. You can also compare other research materials in the research peptide catalog. Documentation and listed specifications can change by lot.

What Is AOD-9604?

AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone (hGH), specifically amino acids 177-191 from the C-terminal region. That's the tail end of the HGH molecule - the part researchers identified as responsible for HGH's lipolytic (fat-burning) activity.

The sequence includes a modification intended for experimental investigation. Researchers should verify the exact sequence and molecular form against the supplier record and the primary literature rather than infer activity from the compound name.

AOD-9604 was originally developed by Professor Frank Ng at Monash University in Australia during the 1990s, and it's been through more rigorous clinical investigation than most research peptides on the market.

How AOD-9604 Works: Mechanism of Action

Published studies have investigated AOD-9604 in models related to lipid metabolism. Those findings are model- and protocol-specific and do not establish a therapeutic effect for a research product.

The Lipolytic Pathway

Preclinical literature has examined endpoints including:

1. Stimulating lipolysis - the breakdown of triglycerides stored in adipose (fat) tissue into free fatty acids and glycerol
2. Inhibiting lipogenesis - the process by which the body converts non-fat food sources into stored fat
3. Activating beta-3 adrenergic receptors - these receptors, found primarily on fat cells, trigger the release of stored fatty acids when activated

These are research endpoints, not guaranteed properties of every lot and not evidence for personal use.

What It Doesn't Do (And Why That Matters)

Study authors have compared selected growth-hormone-pathway, glucose, and tolerability markers under specific trial conditions. Those limited observations should not be generalized into claims of absent risk, receptor selectivity, or clinical safety outside the studied protocol.

What Does the Research Show?

AOD-9604 has a more substantial clinical research base than most peptides in the research market. Here's what stands out:

Fat Metabolism Studies

The foundational research comes from Monash University. In obese Zucker rats (a standard model for metabolic research), AOD-9604 produced significant reductions in body fat without affecting food intake, growth rate, or lean mass. The fat loss was selective - it preferentially targeted visceral and subcutaneous adipose tissue.

A 2001 study published in the Journal of Endocrinology showed that AOD-9604 stimulated lipolysis in both human and murine adipose tissue at concentrations as low as 10 nanomolar. Importantly, the anti-lipogenic effect was confirmed independently of the lipolytic activity - meaning it works on both sides of the fat storage equation simultaneously.

Human Clinical Trials

AOD-9604 made it to Phase 2b clinical trials for obesity - further than most research peptides ever get. The trials, conducted by Metabolic Pharmaceuticals Limited:

• Phase 1 - Safety established. No serious adverse events. No effect on IGF-1 or glucose levels.
• Phase 2a - Dose-ranging study showed statistically significant fat loss compared to placebo over 12 weeks.
• Phase 2b - Larger trial (300+ participants). Results were mixed - the primary endpoint wasn't met in the intention-to-treat analysis, but subgroup analyses showed significant effects at specific doses, particularly in participants with higher baseline BMI.

The Phase 2b results led to the program being shelved for obesity as a standalone indication. But researchers have noted methodological concerns with the trial design that may have masked real effects - including a high placebo response rate and short duration.

Cartilage and Joint Research

This is where AOD-9604 research has taken an interesting turn. Studies have shown that AOD-9604 stimulates proteoglycan and collagen synthesis in cartilage cells. A 2020 study demonstrated that intra-articular injection of AOD-9604 significantly improved cartilage repair in an animal model of osteoarthritis.

Published cartilage work includes laboratory and animal models. It does not establish an approved therapeutic application for material sold as a research product.

This dual application - metabolic and musculoskeletal - makes AOD-9604 unusually versatile among research peptides.

AOD-9604 vs HGH Fragment 176-191

You'll see these two discussed interchangeably, but they're not identical:

The tyrosine modification in AOD-9604 isn't cosmetic - it meaningfully changes the peptide's pharmacological profile. If you're comparing the two for research purposes, AOD-9604 has substantially more published data behind it.

Protocol Variables in Published Literature

Published studies use different models, routes, concentrations, controls, and endpoints. Those parameters are study-specific and should not be copied into human or personal-use protocols. Researchers should consult the primary source and an approved institutional protocol for the exact experimental design.

Key variables to record include the test system, material lot, sequence/form, analytical identity method, concentration calculation, comparator, exposure schedule, sampling plan, and endpoint definition. Human clinical-trial parameters do not establish a consumer-use protocol for a research product.

Reconstitution

AOD-9604 may be supplied as a lyophilized research material. Solvent choice, concentration, storage, and discard criteria must come from the lot documentation and the laboratory's validated protocol. See the reconstitution guide for concentration-math and documentation checks, not universal preparation instructions.

Storage and Handling

AOD-9604 handling requirements depend on form, formulation, container, transport history, and the specific lot documentation. Do not infer identity, purity, or usability from appearance alone. Record receipt conditions, follow the supplier's lot-specific storage statement, and define any post-preparation hold time in the laboratory protocol.

For a deep dive on proper peptide storage, check our storage guide.

Safety Evidence and Study Limits

AOD-9604 has been evaluated in published preclinical work and human clinical trials, but those studies do not establish that a research-use-only product is safe for personal use. Reported findings must be interpreted within each study's population, dose, formulation, duration, and monitoring plan.

Clinical-trial reports describe monitored adverse events and laboratory markers for defined study populations. A researcher reviewing those reports should check sample size, comparator, exposure duration, attrition, and confidence intervals rather than converting a limited observation into a blanket safety claim.

Regulatory status is jurisdiction- and use-specific and can change. It should not be treated as proof that a research product is approved for human consumption or therapeutic use.

Who's Researching AOD-9604?

Interest in AOD-9604 spans several research domains:

• Metabolic researchers - investigating targeted fat reduction without hormonal disruption
• Orthopedic/sports medicine - exploring cartilage repair and joint regeneration
• Longevity researchers - interested in metabolic optimization without the risks of full HGH replacement
• Lipedema researchers - investigating whether AOD-9604's selective lipolysis could help with this poorly understood condition

Quality Considerations

AOD-9604 is widely available, but quality varies dramatically. Key things for researchers to verify:

• Certificate of Analysis (COA) - verify the reported purity method, lot number, date, and laboratory rather than relying on a universal threshold. Learn how to read one in our COA guide.
• Mass spectrometry data - confirms correct molecular weight (1817.12 Da for the free acid form)
• Endotoxin testing - especially important for injectable research applications
• Source verification - ensure the supplier manufactures or sources from GMP-compliant facilities

The Bottom Line

AOD-9604 has both preclinical literature and historical human clinical-trial records, but the evidence is mixed and protocol-specific. That makes careful source review, material identification, and lot matching more important than broad efficacy or safety summaries.

The Phase 2b program did not meet its primary endpoint. Any further laboratory work should start from that limitation and define a falsifiable endpoint rather than assume a favorable effect.

For analytical procurement, the immediate questions are whether the material identity, sequence, mass, purity method, and report lot are documented clearly enough for the planned protocol.

This article is for educational and research purposes only. AOD-9604 is sold as a research compound and is not approved for human therapeutic use in most jurisdictions. Always ensure compliance with local regulations when purchasing research peptides.

Review the current AOD-9604 research listing, the broader research peptide catalog, and available lot documentation in the lab-report index. A listed specification is not a substitute for matching the report to the material lot.

Next documentation checks:

• AOD-9604 research product
• Research peptide catalog
• Lab-report index
• How to read a peptide COA